Theravance Biopharma, Inc.
NGM: TBPHLive Quote
📈 ZcoreAI Score
Our AI model analyzes Theravance Biopharma, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TBPH Z-Score →About Theravance Biopharma, Inc.
Healthcare
Biotechnology
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
📊 Fundamental Analysis
Theravance Biopharma, Inc. demonstrates exceptional profitability, with a profit margin of 98.5%.
The company recently reported 144.7% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is 44.8%, which reflects exceptional capital efficiency.
At a current price of $16.35, TBPH currently sits at the 63rd percentile of its 52-week range (Range: $8.31 - $21.03).
💰 Valuation Insight
TBPH trades at a 68.3% discount (PE: 7.94), which may represent a value opportunity given the sector average of 25.00. Analysts anticipate some earnings pressure, with a higher forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
✅
Return on Equity
Excellent
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$841.91M
Trailing P/E
7.94
Forward P/E
12.07
Beta (5Y)
0.17
52W High
$21.03
52W Low
$8.31
Avg Volume
627K
Day High
Day Low